---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041987"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:34:13.607297+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharma licenses Ketamir-2, gets $3M loan from MIRALOGX; appoints new director

## Summary
- Exclusive license for Ketamir-2 (oral ketamine analog) in North America; $100k upfront, 8% royalties.
- MIRALOGX provides $3M line of credit to fund Ketamir-2 IND development; 8% interest, one-year term.
- MIRA issues warrant for 700k shares at $2.00 per share, exercisable through Nov 15, 2028.
- Michael Jerman appointed to Board, Audit Committee, and Compensation Committee effective Nov 14, 2023.
- DEA determined Ketamir-2 is not a controlled substance; potential for home self-administration.

## SEC filing metadata
- accession: 0001493152-23-041987
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041987
- JSON: https://secwatch.observer/filing/0001493152-23-041987.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041987.txt

## Key facts
- Debt Financings
  MIRA PHARMACEUTICALS, INC. incurred loan of up to $3.0 million with MIRALOGX at annual fixed rate of 8% maturing November 15, 2023.
  - Instrument: loan
  - Principal: up to $3.0 million
  - Counterparty: MIRALOGX
  - Rate: annual fixed rate of 8%
  - Maturity: November 15, 2023
  - Event: incurrence
  source text: On November 15, 2023, the Company entered into a Promissory Note and Loan Agreement (the "Loan Agreement") with MIRALOGX. Pursuant to the Loan Agreement, the Company may borrow up to $3.0 million from MIRALOGX to fund the development of licensed products under the License Agreement (the "Loan").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm
- Executive change
  Michael Jerman was appointed as Director at MIRA PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Director
  source text: On November 14, 2023, the Board of Directors of the Company increased the number of directors on the Board from 7 directors to 8 directors and unanimously approved the election and appointment of Mr. Michael Jerman to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm
- Material Agreements
  MIRA PHARMACEUTICALS, INC. entered into Promissory Note and Loan Agreement with MIRALOGX, LLC valued at Up to $3.0 million borrowing capacity; interest at 8% per annum; one-year term; repayment due Novemb (effective 2023-11-15).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: MIRALOGX, LLC
  - Value: Up to $3.0 million borrowing capacity; interest at 8% per annum; one-year term; repayment due Novemb
  - Effective: 2023-11-15
  source text: On November 15, 2023, the Company entered into a Promissory Note and Loan Agreement (the “Loan Agreement”) with MIRALOGX. Pursuant to the Loan Agreement, the Company may borrow up to $3.0 million from MIRALOGX to fund the development of licensed products under the License Agreement (the “Loan”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm
- Material Agreements
  MIRA PHARMACEUTICALS, INC. entered into Exclusive License Agreement with MIRALOGX, LLC valued at $100,000 upfront payment plus quarterly royalties of 8% of net sales and 8% of other revenue; issuan (effective 2023-11-15).
  - Action: entry
  - Agreement: license
  - Counterparty: MIRALOGX, LLC
  - Value: $100,000 upfront payment plus quarterly royalties of 8% of net sales and 8% of other revenue; issuan
  - Effective: 2023-11-15
  source text: On November 15, 2023 (the “Effective Date”), MIRA Pharmaceuticals, Inc. (the “Company”) and MIRALOGX, LLC, a Florida limited liability company (“MIRALOGX”), entered into an exclusive license agreement (the “License Agreement”) to develop and commercialize a drug product containing 2-(2- chlorophenyl)-2-(methylamino) cyclopentan-1-one (sometimes referred to by the Parties as “M209” or “KETAMIR-2”) (“the Product”) as an active agent in North America.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.